MRI monitoring of transplanted neonatal porcine islets labeled with polyvinylpyrrolidone-coated superparamagnetic iron oxide nanoparticles in a mouse model.
islet graft rejection
islet transplantation
neonatal porcine islets
type 1 diabetes mellitus
xenotransplantation
Journal
Xenotransplantation
ISSN: 1399-3089
Titre abrégé: Xenotransplantation
Pays: Denmark
ID NLM: 9438793
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
revised:
25
09
2021
received:
04
05
2021
accepted:
22
10
2021
pubmed:
2
12
2021
medline:
26
4
2022
entrez:
1
12
2021
Statut:
ppublish
Résumé
Islet transplantation is a potential treatment option for certain patients with type 1 diabetes; however, it still faces barriers to widespread use, including the lack of tools to monitor islet grafts post-transplantation. This study investigates whether labeling neonatal porcine islets (NPI) with polyvinylpyrrolidone-coated superparamagnetic iron oxide nanoparticles (PVP-SPIO) affects their function, and whether this nanoparticle can be utilized to monitor NPI xenografts with magnetic resonance imaging (MRI) in a mouse model. In vitro, PVP-SPIO-labeled NPI in an agarose gel was visualized clearly by MRI. PVP-SPIO-labeled islets were then transplanted under the kidney capsules of immunodeficient nondiabetic and diabetic mice. All diabetic mice that received transplantation of PVP-SPIO-labeled islets reached normoglycemia. Grafts appeared as hypo-intense areas on MRI and were distinguishable from the surrounding tissues. Following injection of spleen cells from immunocompetent mice, normoglycemic recipient mice became diabetic and islet grafts showed an increase in volume, accompanied by a mixed signal on MRI. Overall, this study demonstrates that PVP-SPIO did not affect the function of NPI that PVP-SPIO-labeled islets were easily seen on MRI, and changes in MRI signals following rejection suggest a potential use of PVP-SPIO-labeled islets to monitor graft viability.
Substances chimiques
Povidone
FZ989GH94E
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e12720Informations de copyright
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Shapiro AMJ, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med. 2006;355(13):1318-1330.
Andersen DK. The practical importance of recognizing pancreaticogenic or type 3c diabetes. Diabetes Metab Res Rev. 2012;28(4):326-328.
Pepper AR, Bruni A, Shapiro AMJ. Clinical islet transplantation: is the future finally now?. Curr Opin Organ Transplant. 2018;23(4):428-439.
Wang P, Schuetz C, Vallabhajosyula P, et al. Monitoring of allogeneic islet grafts in nonhuman primates using magnetic resonance imaging. Transplantation. 2015;99(8):1574-1581.
Titus N, Badet L, Gray DW. Islet cell transplantation for insulin-dependent diabetes mellitus: perspectives from the present and prospects for the future. Expert Rev Mol Med. 2000;2(6):1-28.
Pileggi A, Ricordi C, Alessiani M, Inverardi L. Factors influencing islet of Langerhans graft function and monitoring. Clin Chim Acta. 2001;310(1):3-16.
Emamaullee JA, Shapiro AMJ. Factors influencing the loss of β-cell mass in islet transplantation. Cell Transplant. 2007;16(1):1-8.
Sakata N, Yoshimatsu G, Tsuchiya H, et al. Imaging of transplanted islets by positron emission tomography, magnetic resonance imaging, and ultrasonography. Islets. 2013;5(5):179-187.
Borot S, Crowe LA, Parnaud G, et al. Quantification of islet loss and graft functionality during immune rejection by 3-tesla MRI in a rat model. Transplantation. 2013;96(5):438-444.
Berney T, Toso C. Monitoring of the islet graft. Diabetes Metab. 2006;32:503-512.
Paty BW, Bonner-Weir S, Laughlin MR, McEwan AJ, Shapiro AMJ. Toward development of imaging modalities for islets after transplantation: insights from the National Institutes of Health workshop on beta cell imaging. Transplantation. 2004;77(8):1133-1137.
Evgenov NV, Medarova Z, Dai G, Bonner-Weir S, Moore A. In vivo imaging of islet transplantation. Nat Med. 2006;12(1):144-148.
Evgenov NV, Medarova Z, Pratt J, et al. In vivo imaging of immune rejection in transplanted pancreatic islets. Diabetes. 2006;55(9):2419-2428.
Thorek DLJ, Chen AK, Czupryna J, Tsourkas A. Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann Biomed Eng. 2006;34(1):23-38.
Arbab AS, Wilson LB, Ashari P, Jordan EK, Lewis BK, Frank JA. A model of lysosomal metabolism of dextran coated superparamagnetic iron oxide (SPIO) nanoparticles: implications for cellular magnetic resonance imaging. NMR Biomed. 2005;18(6):383-389.
Jung MJ, Lee SS, Hwang YH, et al. MRI of transplanted surface-labeled pancreatic islets with heparinized superparamagnetic iron oxide nanoparticles. Biomaterials. 2011;32(35):9391-9400.
Delcroix GJR, Jacquart M, Lemaire L, et al. Mesenchymal and neural stem cells labeled with HEDP-coated SPIO nanoparticles: in vitro characterization and migration potential in rat brain. Brain Res. 2009;1255:18-31.
Kriz J, Jirak D, Berkova Z, et al. Detection of pancreatic islet allograft impairment in advance of functional failure using magnetic resonance imaging. Transpl Int. 2012;25(2):250-260.
Malosio ML, Esposito A, Brigatti C, et al. MR imaging monitoring of iron-labeled pancreatic islets in a small series of patients: islet fate in successful, unsuccessful, and autotransplantation. Cell Transplant. 2015;24(11):2285-2296.
Huang H, Xie Q, Kang M, et al. Labeling transplanted mice islet with polyvinylpyrrolidone coated superparamagnetic iron oxide nanoparticles for in vivo detection by magnetic resonance imaging. Nanotechnology. 2009;20(36):365101.
Jirák D, Kríz J, Herynek V, et al. MRI of transplanted pancreatic islets. Magn Reson Med. 2004;52(6):1228-1233.
Wang P, Goodwill PW, Pandit P, et al. Magnetic particle imaging of islet transplantation in the liver and under the kidney capsule in mouse models. Quant Imaging Med Surg. 2018;8(2):114-122.
Toso C, Vallee JP, Morel P, et al. Clinical magnetic resonance imaging of pancreatic islet grafts after iron nanoparticle labeling. Am J Transplant. 2008;8(3):701-706.
Kim SH, Kim H, Park KS, Moon WK. Evaluation of porcine pancreatic islets transplanted in the kidney capsules of diabetic mice using a clinically approved super paramagnetic iron oxide (SPIO) and a 1.5t MR scanner. Korean J Radiol. 2010;11(6):673-682.
Juang JH, Shen CR, Wang JJ, et al. Magnetic resonance imaging of mouse islet grafts labeled with novel chitosan-coated superparamagnetic iron oxide nanoparticles. PLoS One. 2013;8(4):e62626.
Ris F, Lepetit-Coiffe M, Meda P, et al. Assessment of human islet labeling with clinical grade iron nanoparticles prior to transplantation for graft monitoring by MRI. Cell Transplant. 2010;19(12):1573-1585.
Saudek F, Jirák D, Girman P, et al. Magnetic resonance imaging of pancreatic islets transplanted into the liver in humans. Transplantation. 2010;90(12):1602-1606.
Kriz J, Jirák D, Girman P, et al. Magnetic resonance imaging of pancreatic islets in tolerance and rejection. Transplantation. 2005;80(11):1596-1603.
Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after clinical islet transplantation. Diabetes. 2005;54(7):2060-2069.
Alejandro R, Barton FB, Hering BJ, Wease S. 2008 Update from the collaborative islet transplant registry. Transplantation. 2008;86(12):1783-1788.
MacKenzie DA, Hullett DA, Sollinger HW. Xenogeneic transplantation of porcine islets: an overview. Transplantation. 2003;76(6):887-891.
Emamaullee JA, Shapiro AMJ, Rajotte RV, Korbutt G, Elliott JF. Neonatal porcine islets exhibit natural resistance to hypoxia-induced apoptosis. Transplantation. 2006;82(7):945-952.
Korbutt GS, Elliott JF, Ao Z, Smith DK, Warnock GL, Rajotte RV. Large scale isolation, growth, and function of porcine neonatal islet cells. J Clin Invest. 1996;97(9):2119-2129.
Joo HT, Foster P, Rosales A, et al. Imaging islets labeled with magnetic nanoparticles at 1.5 Tesla. Diabetes. 2006;55(11):2931-2938.
Rayat GR, Gill RG. Indefinite survival of neonatal porcine islet xenografts by simultaneous targeting of LFA-1 and CD154 or CD45RB. Diabetes. 2005;54(2):443-451.
Arefanian H, Tredget EB, Rajotte RV, Gill RG, Korbutt GS, Rayat GR. Short-term administrations of a combination of anti-LFA-1 and anti-CD154 monoclonal antibodies induce tolerance to neonatal porcine islet xenografts in mice. Diabetes. 2010;59(4):958-966.
Arefanian H, Tredget EB, Rajotte RV, Korbutt GS, Gill RG, Rayat GR. Combination of anti-CD4 with anti-LFA-1 and anti-CD154 monoclonal antibodies promotes long-term survival and function of neonatal porcine islet xenografts in spontaneously diabetic NOD mice. Cell Transplant. 2007;16(8):787-798.
Rayat GR, Johnson ZA, Beilke JN, Korbutt GS, Rajotte RV, Gill RG. The degree of phylogenetic disparity of islet grafts dictates the reliance on indirect CD4 T-cell antigen recognition for rejection. Diabetes. 2003;52(6):1433-1440.
Zhang B, Jiang B, Chen Y, et al. Detection of viability of transplanted beta cells labeled with a novel contrast agent - polyvinylpyrrolidone-coated superparamagnetic iron oxide nanoparticles by magnetic resonance imaging. Contrast Media Mol Imaging. 2012;7(1):35-44.
Smood B, Bottino R, Hara H, Cooper DKC. Is the renal subcapsular space the preferred site for clinical porcine islet xenotransplantation? Review article. Int J Surg. 2019;69:100-107.
Zacharovová K, Berková Z, Jirák D, et al. Processing of superparamagnetic iron contrast agent ferucarbotran in transplanted pancreatic islets. Contrast Media Mol Imaging. 2012;7(6):485-493.
van Osch MJP, Webb AG. Safety of ultra-high field MRI: what are the specific risks?. Curr Radiol Rep. 2014;2(8):61.
Weissleder R, Stark DD, Engelstad BL, et al. Superparamagnetic iron oxide: pharmacokinetics and toxicity. Am J Roentgenol. 1989;152(1):167-173.
Vega P, Valentín F, Cubiella J. Colorectal cancer diagnosis: pitfalls and opportunities. World J Gastrointest Oncol. 2015;7(12):422.
Itescu S, Kwiatkowski P, Artrip JH, et al. Role of natural killer cells, macrophages, and accessory molecule interactions in the rejection of pig-to-primate xenografts beyond the hyperacute period. Hum Immunol. 1998;59(5):275-286.
Huo Q, Zhou M, Cooper DKC, Dai Y, Xie N, Mou L. Circulating miRNA or circulating DNA-potential biomarkers for organ transplant rejection. Xenotransplantation. 2019;26:e12444.
Zhou M, Lu Y, Zhao C, et al. Circulating pig-specific DNA as a novel biomarker for monitoring xenograft rejection. Xenotransplantation. 2019;26(4):1-12.
Dinnyes A, Schnur A, Muenthaisong S, et al. Integration of nano- and biotechnology for beta-cell and islet transplantation in type-1 diabetes treatment. Cell Prolif. 2020;53(5):1-9.